Clinical predictors of cardiac toxicity in HER2-positive early breast cancer patients treated with adjuvant s.c. versus i.v. trastuzumab

BACKGROUND: Few data are available about real-life cardiotoxicity associated with s.c. versus i.v. trastuzumab treatment of early-stage, HER2-positive breast cancer, and little is known about its predisposing factors. PATIENTS AND METHODS: We retrospectively reviewed data of 363 adult patients treat...

Descripción completa

Detalles Bibliográficos
Autores principales: De Sanctis, Rita, Giordano, Laura, D’Antonio, Federica, Agostinetto, Elisa, Marinello, Arianna, Guiducci, Daniela, Masci, Giovanna, Losurdo, Agnese, Zuradelli, Monica, Torrisi, Rosalba, Santoro, Armando
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8022886/
https://www.ncbi.nlm.nih.gov/pubmed/33780903
http://dx.doi.org/10.1016/j.breast.2021.03.004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8022886/
https://www.ncbi.nlm.nih.gov/pubmed/33780903
http://dx.doi.org/10.1016/j.breast.2021.03.004

Ejemplares similares